Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?

Novo (NVO) has faced a challenging period in recent years as it lost market share in the GLP-1 industry, resulting in a more than 60% decline in its share price. Currently, Novo is trading at 11.8x forward earnings, which is significantly lower than the 18.6x average for healthcare stocks. While this may appear attractive at first glance, it is unclear whether Novo's share price is truly undervalued or if it is simply a value trap.

The primary source of Novo's revenue comes from its GLP-1 products, specifically Wegovy and Ozempic. However, competition from Eli Lilly (LLY) has resulted in declining sales growth for both of these products. Moreover, Novo has experienced several clinical setbacks, which have raised concerns about its ability to maintain its leadership position in the GLP-1 market.

For instance, CagriSema, a highly effective GLP-1 drug, did not meet the company's 25% mean weight-loss target in a Phase 3 study and was outperformed by Eli Lilly's Zepbound in a head-to-head weight-loss clinical trial. Despite a potential approval by the end of the year, these setbacks may prevent Novo from closing the gap with its competitor.

Additionally, Novo's attempts to diversify its pipeline have not yielded the desired results. For example, ziltivekimab, an investigational drug intended to reduce major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation, failed to demonstrate significant efficacy in a Phase 3 clinical trial.

This setback, along with another promising investigational medicine, zenagamtide, which showed impressive results in a Phase 1b/2a study, highlights the challenges Novo faces in developing new products to bolster its position in the market.